Eyes On Kiora - ABACUS-2 And KLARITY Data Readouts Due In 2027

Core Insights - Kiora Pharmaceuticals (KPRX) is a clinical-stage biopharmaceutical company focused on developing advanced treatments for retinal diseases [2] Drug Candidates - Kiora has two drug candidates: KIO-301 for inherited retinal diseases and KIO-104 for retinal inflammation [2][7] - KIO-301 targets surviving retinal ganglion cells to restore visual function in patients with retinitis pigmentosa [3] - KIO-104 suppresses T-cells and cytokines to reduce inflammation in the eye [7] Clinical Trials - KIO-301 is undergoing a Phase 2 clinical trial (ABACUS-2) to assess safety, tolerability, and efficacy in patients with late-stage retinitis pigmentosa, enrolling 36 patients [3][4] - KIO-104 is in a Phase 2 clinical trial (KLARITY) for retinal macular edema, with plans to enroll up to 28 patients [8][9] - Results from both clinical trials are expected in early 2027 [10] Financial Position - Kiora ended Q2 2025 with $20.7 million in cash and equivalents, plus $3.1 million in receivables and tax credits, providing a cash runway through late 2027 [11] Company Background - Kiora Pharmaceuticals was formerly known as EyeGate Pharmaceuticals Inc. and rebranded on November 8, 2021 [12] - The company's stock has traded between $2.21 and $4.18 over the past year, closing at $2.47, up 6.93% [12]